Related Experiment Videos
Clinical and cytogenetic features in six patients with chronic myelogenous leukemia and a complex Philadelphia
Insights
This study of chronic myelogenous leukemia (CML) patients with complex Philadelphia (Ph1) translocations found outcomes similar to those with standard Ph1. Survival and clinical findings did not differ significantly, suggesting complex translocations do not alter CML prognosis.
Area of Science:
- Hematology
- Oncology
- Cytogenetics
Background:
- Chronic myelogenous leukemia (CML) is characterized by the Philadelphia chromosome (Ph1).
- Complex Ph1 translocations involve more than two chromosomal partners.
- The prognostic impact of complex Ph1 translocations in CML is not well-defined.
Purpose of the Study:
- To describe clinical, hematologic, and cytogenetic findings in CML patients with complex Ph1 translocations.
- To compare the outcomes of patients with complex Ph1 translocations to those with standard Ph1.
- To assess the impact of additional chromosomal aberrations during blastic crisis.
Main Methods:
- Case series describing six patients with CML and complex Ph1 translocations.
- Detailed cytogenetic analysis of Ph1 translocations (three-way and five-way).
- Monitoring of clinical and hematologic parameters, including survival time and chromosomal aberrations during blastic crisis.
Main Results:
- Five patients had three-way Ph1 translocations; one had a five-way translocation.
- Four of five patients developed additional chromosomal aberrations during blastic crisis.
- Median survival was 42 months; one patient died of myocardial infarction at 23.5 months.
Conclusions:
- Complex Ph1 translocations in CML do not appear to significantly alter clinical, hematologic, or cytogenetic findings compared to standard Ph1.
- Additional chromosomal aberrations during blastic crisis may occur but do not seem to change the overall prognosis.
- Further research is warranted to fully understand the implications of complex Ph1 translocations in CML.
Abstract:
Six patients with chronic myelogenous leukemia and a complex Philadelphia (Ph1) translocation are described. The complex Ph1 translocations were a three-way translocation in five patients and a five-way translocation in one. Additional chromosomal aberrations were detected in four of five patients when the blastic crisis supervened. The median survival time was 42 months. The remaining patient died of acute myocardial infarction 23.5 months after the diagnosis of CML was made. There seems no difference between these six patients and those with the standard Ph1 with respect to clinical, hematologic and cytogenetic findings.